Pharmacological Reviews Get Tables of Contents delivered automatically
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clark, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clark, W. G.

Pharmacological Reviews, Vol 11, 330-349, Copyright © 1959 by the American Society for Pharmacology and Experimental Therapeutics

STUDIES ON INHIBITION OF L-DOPA DECARBOXYLASE IN VITRO AND IN VIVO

W. G. Clark 1

1 Pharmacology and Physiology Section, Veterans Administration Center and Medical Center, University of California, Los Angeles, California

Studies relating to the inhibition in vitro are reviewed, with some emphasis on inactivation of coenzyme by the substrate and its analogues, and on carbonyl trapping agents, but more specifically on analogues of certain hydroxycinnamic acids which inhibit dopa-, dops- and 5-HTP-decarboxylases. The structural features of such inhibitors are analyzed, as well as their specificity and competitive nature.

The nature and characteristics of dopa decarboxylation in vivo are discussed, particularly as affected by the absence of visceral organs, and by the thyroid hormone, adrenal cortex, sex and vitamin B6.

A review and analysis is made of the work pointing to changes in apoenzyme and coenzyme caused by hyperthyroidism and vitamin B6 deficiency.

Chemical and pharmacological evidence is presented which shows that the substances which inhibit dopa decarboxylase in vitro also are generally effective in vivo. Twenty-five in vitro inhibitors and 50 structurally related noninhibitors have been assessed in several hundred animals. This has led to an understanding of the structural requirements for effective inhibition in vivo, which are essentially the same as for inhibition in vitro.

A possible alternate biosynthetic route to noradrenaline and adrenaline may be by transamination of hydroxyphenylpyruvic acids and subsequent decarboxylation of the resulting amino acids, which is blocked by the inhibitors at the decarboxylation step.

The duration of inhibition and the detoxication of the inhibitors have been studied, and various structural modifications and pharmacological procedures have been investigated for prolonging the duration of the inhibition.

One inhibitor was shown to inhibit the biosynthesis of adrenal medullary adrenaline in insulin-treated rats.




This article has been cited by other articles:


Home page
ScienceHome page
J. A. Oates, L. Gillespie, S. Udenfriend, and A. Sjoerdsma
Decarboxylase Inhibition and Blood Pressure Reduction by agr-Methyl-3,4-Dihydroxy-DL-phenylalanine
Science, June 24, 1960; 131(3417): 1890 - 1891.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition